Beam Therapeutics Inc (BEAM)

$16.64 +0.63 (3.94%)
Market Cap 1.68B
Revenue (ttm) 63.52M
Net Income (ttm) -376.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -593.10%
Debt to Equity Ratio 0.00
Volume 2,393,900
Avg Vol 2,387,682
Day's Range N/A - N/A
Shares Out 101.16M
Stochastic %K 40%
Beta 2.22
Analysts Strong Sell
Price Target $43.80

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 327 8775
Website: beamtx.com
Address:
238 Main Street, Cambridge, United States
CelticBeast
CelticBeast Aug. 23 at 4:50 PM
$BEAM soon to be double the price
0 · Reply
wrengler4
wrengler4 Aug. 23 at 10:51 AM
$BEAM $CRSP $NTLA $PRME Speeches are just that, Promos to suck you all in , 30 years before anything is done
3 · Reply
PortfolioAutopsy
PortfolioAutopsy Aug. 23 at 7:12 AM
$BEAM Beam Therapeutics Inc is a gene editing company with promising technology but early clinical stage
0 · Reply
360sage
360sage Aug. 23 at 1:01 AM
$PRME $BEAM Impressive speech, and progress, by Dr. David Liu. Gene therapies can revolutionize healthcare/medicine. $NTLA $CRSP https://youtu.be/Z3OM5cYCZHE?si=e1yD1ccGSRVREkND
0 · Reply
lzwa
lzwa Aug. 22 at 9:31 PM
$BEAM $35
0 · Reply
lzwa
lzwa Aug. 22 at 9:29 PM
$BEAM still so cheap :o
0 · Reply
Blizzy
Blizzy Aug. 22 at 5:55 PM
$BEAM kinda disappointing that this hasn’t juiced more with the market today and telegraphed rate cuts 
0 · Reply
Tumble51
Tumble51 Aug. 22 at 4:56 PM
$BEAM $NTLA LMAO !!!
0 · Reply
wrengler4
wrengler4 Aug. 22 at 4:52 PM
$BEAM $NTLA Just as dogs piss on shoes , lol
0 · Reply
CashCashBaby
CashCashBaby Aug. 22 at 3:56 PM
$BEAM $25 by end of September! Wrote it on the wall
0 · Reply
Latest News on BEAM
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Aug 14, 2025, 7:00 AM EDT - 10 days ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

Aug 5, 2025, 7:00 AM EDT - 19 days ago

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases

Jun 20, 2025, 10:07 AM EDT - 2 months ago

Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Jun 13, 2025, 7:00 AM EDT - 2 months ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Jun 3, 2025, 7:00 AM EDT - 2 months ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 29, 2025, 4:01 PM EDT - 3 months ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

May 14, 2025, 9:30 AM EDT - 3 months ago

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

May 13, 2025, 7:00 AM EDT - 3 months ago

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 12, 2025, 4:01 PM EDT - 3 months ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 6, 2025, 7:00 AM EDT - 3 months ago

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

Apr 5, 2025, 7:00 AM EDT - 5 months ago

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard

Mar 31, 2025, 2:25 PM EDT - 5 months ago

Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard

MRNA

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Mar 27, 2025, 4:01 PM EDT - 5 months ago

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy

Mar 21, 2025, 1:13 PM EDT - 5 months ago

Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity

Mar 10, 2025, 9:07 AM EDT - 5 months ago

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity

Beam Therapeutics Announces Pricing of Underwritten Offering

Mar 10, 2025, 6:01 AM EDT - 5 months ago

Beam Therapeutics Announces Pricing of Underwritten Offering

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

Mar 10, 2025, 6:00 AM EDT - 5 months ago

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Feb 25, 2025, 7:00 AM EST - 6 months ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

Feb 24, 2025, 7:00 AM EST - 6 months ago

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 7:00 AM EST - 7 months ago

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

Jan 23, 2025, 7:00 AM EST - 7 months ago

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Jan 13, 2025, 7:00 AM EST - 7 months ago

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Dec 8, 2024, 1:45 PM EST - 9 months ago

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Dec 7, 2024, 11:30 AM EST - 9 months ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

Dec 6, 2024, 7:00 AM EST - 9 months ago

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Dec 4, 2024, 7:00 AM EST - 9 months ago

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

Nov 12, 2024, 4:01 PM EST - 10 months ago

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch

Nov 7, 2024, 2:25 PM EST - 10 months ago

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch

Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 11:54 AM EST - 10 months ago

Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

Nov 5, 2024, 6:30 AM EST - 10 months ago

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

Oct 29, 2024, 6:30 AM EDT - 10 months ago

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

Aug 6, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

Beam Therapeutics Announces Transition of Chief Financial Officer

Jul 15, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Announces Transition of Chief Financial Officer

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

Jun 26, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

Jun 14, 2024, 3:00 AM EDT - 1 year ago

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

May 30, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

May 14, 2024, 4:00 PM EDT - 1 year ago

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

May 8, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

May 7, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Mar 26, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

Feb 28, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

Feb 27, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 5, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

Jan 8, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

Dec 14, 2023, 6:30 AM EST - 1 year ago

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

CRISPR Gene Editing: Beam Therapeutics

Nov 30, 2023, 4:36 AM EST - 1 year ago

CRISPR Gene Editing: Beam Therapeutics

Beam Therapeutics: Sale Of Rights To Verve's In-Vivo Candidates An Odd Decision

Nov 10, 2023, 4:50 PM EST - 1 year ago

Beam Therapeutics: Sale Of Rights To Verve's In-Vivo Candidates An Odd Decision

Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference

Nov 8, 2023, 6:30 AM EST - 1 year ago

Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results

Nov 8, 2023, 6:30 AM EST - 1 year ago

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results

CelticBeast
CelticBeast Aug. 23 at 4:50 PM
$BEAM soon to be double the price
0 · Reply
wrengler4
wrengler4 Aug. 23 at 10:51 AM
$BEAM $CRSP $NTLA $PRME Speeches are just that, Promos to suck you all in , 30 years before anything is done
3 · Reply
PortfolioAutopsy
PortfolioAutopsy Aug. 23 at 7:12 AM
$BEAM Beam Therapeutics Inc is a gene editing company with promising technology but early clinical stage
0 · Reply
360sage
360sage Aug. 23 at 1:01 AM
$PRME $BEAM Impressive speech, and progress, by Dr. David Liu. Gene therapies can revolutionize healthcare/medicine. $NTLA $CRSP https://youtu.be/Z3OM5cYCZHE?si=e1yD1ccGSRVREkND
0 · Reply
lzwa
lzwa Aug. 22 at 9:31 PM
$BEAM $35
0 · Reply
lzwa
lzwa Aug. 22 at 9:29 PM
$BEAM still so cheap :o
0 · Reply
Blizzy
Blizzy Aug. 22 at 5:55 PM
$BEAM kinda disappointing that this hasn’t juiced more with the market today and telegraphed rate cuts 
0 · Reply
Tumble51
Tumble51 Aug. 22 at 4:56 PM
$BEAM $NTLA LMAO !!!
0 · Reply
wrengler4
wrengler4 Aug. 22 at 4:52 PM
$BEAM $NTLA Just as dogs piss on shoes , lol
0 · Reply
CashCashBaby
CashCashBaby Aug. 22 at 3:56 PM
$BEAM $25 by end of September! Wrote it on the wall
0 · Reply
CashCashBaby
CashCashBaby Aug. 22 at 3:56 PM
$NTLA $BEAM are the two affordable players in the field with huge upside! Could see a significant uptrend by year end.
0 · Reply
wrengler4
wrengler4 Aug. 22 at 3:42 PM
$BEAM $CRSP $NTLA $RXRX $SOFI So doesn’t América with Epstein and the diddler
1 · Reply
wrengler4
wrengler4 Aug. 22 at 3:41 PM
$BEAM $CRSP $NTLA A sell candidate Loading the wall with short sales !!
2 · Reply
Bubbelkoning
Bubbelkoning Aug. 22 at 2:11 PM
$CRSP $NTLA $BEAM fully loaded up in the past couple of days, boom!
1 · Reply
APman
APman Aug. 22 at 2:05 PM
$NTLA $CRSP $BEAM $RXRX $SOFI Hope this sticks
2 · Reply
TomMac64
TomMac64 Aug. 22 at 11:36 AM
$BEAM $CADL $NTLA $SRPT $VKTX I was just gonna post the same thing ; Everything is the same until it isn’t !
0 · Reply
giuseppe8469
giuseppe8469 Aug. 22 at 11:34 AM
$BEAM $CADL $NTLA $SRPT $VKTX until it’s not!! Good luck pal
1 · Reply
Jadek6
Jadek6 Aug. 22 at 11:33 AM
$CADL $NTLA $BEAM $SRPT $VKTX and others No one wants hype , they want results Time is money and buy outs with CEO perks are dead. Tech is where big money is and has been Biotech only survives with the shorts.
0 · Reply
Brokebroker3
Brokebroker3 Aug. 22 at 12:41 AM
$BEAM could Friday be the day?!?!
1 · Reply
Wintrust
Wintrust Aug. 21 at 4:42 PM
$BEAM is this a good buy? Whats your PT? Thanks ❤️
1 · Reply
AZona
AZona Aug. 21 at 3:58 PM
$BEAM bought some under $16 here ❤️
1 · Reply
Elamenape2
Elamenape2 Aug. 21 at 1:48 PM
$BEAM
0 · Reply